Persistent URL of this record https://hdl.handle.net/1887/3188563
Documents
-
- Download
- Title pages_Contents
- open access
-
- Download
- Chapter 2
- open access
- Full text at publishers site
-
- Download
- Chapter 3
- open access
- Full text at publishers site
-
- Download
- Chapter 4
- open access
- Full text at publishers site
-
- Download
- Chapter 5
- open access
- Full text at publishers site
-
- Download
- Summary in English
- open access
-
- Download
- Summary in Dutch
- open access
-
- Download
- Propositions
- open access
In Collections
This item can be found in the following collections:
Optimizing the sequence of metastatic castration-resistant prostate cancer treatment options
Radium-223 is the first radionuclide with a survival benefit in mCRPC patients, this was concluded based on a study...Show moreOver recent years, several new anti-cancer agents, like enzalutamide, abiraterone and radium-223 were introduced for treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The phase-3 studies evaluating these agents were primarily performed in patients only treated with docetaxel, because the studies were performed in parallel to each other. The efficacy and safety of sequentially treating patients with these new agents was unknown. This thesis describes the efficacy and tolerability of enzalutamide in patients pretreated with docetaxel and abiraterone. Because the response chance of enzalutamide in this cohort was significantly lower, an analysis of patient- and disease characteristics was performed to identify the responders. Also, the efficacy and tolerability of enzalutamide in heavily pretreated patients was also evaluated.
Radium-223 is the first radionuclide with a survival benefit in mCRPC patients, this was concluded based on a study performed in patients treated with docetaxel or treatment-naïve patients. Even though painful bone metastases are the main reason for treatment with radionuclides, the effect of radium-223 on pain was not properly evaluated. This thesis describes the results of the observational ROTOR-registry, which evaluated the efficacy, tolerability, effect on pain and quality of life of Radium-223 in contemporary extensively pretreated mCRPC patients.
Show less
- All authors
- Badrising, S.K.
- Supervisor
- Haanen, J.B.A.G.
- Co-supervisor
- Bergman, A.M.
- Committee
- Gelderblom, A.J.; Geus-Oei, L.F. de; Bleiker, E.M.A.; Moorselaar, R.J.A. van; Wit, R. de; Hulle, T. van der
- Qualification
- Doctor (dr.)
- Awarding Institution
- Faculty of Medicine, Leiden University Medical Center [LUMC], Leiden University
- Date
- 2021-06-15
- ISBN (print)
- 9789464213089
Funding
- Sponsorship
- Bayer BV